Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Liabilities (2016 - 2025)

Amicus Therapeutics' Total Liabilities history spans 16 years, with the latest figure at $675.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 14.32% year-over-year to $675.6 million, compared with a TTM value of $675.6 million through Dec 2025, up 14.32%, and an annual FY2025 reading of $675.6 million, up 14.32% over the prior year.
  • Total Liabilities for Q4 2025 was $675.6 million at Amicus Therapeutics, up from $638.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $675.6 million in Q4 2025, with the low at $559.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $607.3 million, with a median of $604.4 million recorded in 2022.
  • Year-over-year, Total Liabilities soared 68.28% in 2021 and then dropped 4.33% in 2024.
  • Tracing FOLD's Total Liabilities over 5 years: stood at $597.8 million in 2021, then increased by 0.56% to $601.1 million in 2022, then grew by 2.76% to $617.7 million in 2023, then decreased by 4.33% to $591.0 million in 2024, then rose by 14.32% to $675.6 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Total Liabilities are $675.6 million (Q4 2025), $638.4 million (Q3 2025), and $611.0 million (Q2 2025).